Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis

and Market Forecasts to 2016

The Pulmonary Arterial Hypertension Market is Forecast to Show a High Growth Rate
to 2015, but will Diminish in 2016
GlobalData has estimated the global Pulmonary Arterial Hypertension (PAH) market to
have been worth $2,653m in 2009. According to the Venice 2003 revised classification
system, PAH is categorized as World Health Organization (WHO) Group I - PAH. Prior to
2001, no effective drug was approved for the treatment of PAH. Only supportive care
medication such as anticoagulants, diuretics, oxygen, digoxin and calcium channel
blockers were given to the patients. In 2001, the Food and Drug Administration (FDA)
approved Tracleer as the treatment for patients with PAH. This drug was a registered
trademark of Actelion Ltd. The sales of Tracleer grew rapidly due to a high patient
switch over rate. The drug had a better efficacy and safety profile compared to the
previously used off-label drugs. The FDA also approved three more drugs, Remodulin,
Ventavis, and Revatio in 2002, 2004, and 2005 respectively for the treatment of PAH.
However, these three drugs accounted for only a 24% market share to 2005. Between
2005 and 2009, the PAH market grew at a Compound Annual Growth Rate (CAGR) of
39.2% and recorded revenues of $2,653m in 2009. According to GlobalData’s analysis,
the PAH market is forecast to increase at a CAGR of 5% annually over the next six years
to reach $3,569m by 2015. Tracleer, the major revenue generator of the PAH market is
due to go off patent by November 2015. The patent expiry of this drug is expected to
diminish the market in 2016 by 25% to 27%. Until this time, the growth of the PAH
market is primarily attributed to increased competition among existing products, the
release of new and enhanced treatment options, and the development of safer and
more efficacious therapies. The PAH market growth will be further supported by the
increased uptake of promising molecules in the pipeline, combination therapies such as
epoprostenol plus bosentan and epoprostenol plus sildenafil. In 2009, Actelion Ltd, with
its key drug Tracleer, was the leading player in the global PAH market.

For further details, please click or add this link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-
Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Competition in the Pulmonary Arterial Hypertension Market is Expected to Intensify

The leading companies in the global PAH market are Actelion Ltd., Eli Lilly & Co., Gilead
Sciences, Inc., United Therapeutics Corporation, Pfizer, Inc., Genentech, Inc. (Roche),
Bayer Schering Pharma AG, and Quadrant Technologies Limited. Together these
companies accounted for more than 99% of the global PAH market in 2009. Actelion Ltd,
with its blockbuster drug Tracleer, was the market leader with a share of more than 50%
followed by Revatio and Remodulin with 15% each. However, companies such as
Actelion Ltd., United Therapeutics Corporation, Bayer AG, Gilead Sciences, Pfizer Inc.,
Novartis AG, Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Lung RX,
GlaxoSmithKline plc., and Cogentus Pharmaceuticals have the most technologically
advanced products in their pipeline portfolios and are expected to attract the most
investor attention. The global PAH market has seen some intense competition in recent
times, which is expected to further intensify in the coming years.

For further details, please click or add this link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-
Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData, the industry analysis specialist’s new report, “Pulmonary Arterial

Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016", is an
essential source of information and analysis on the global PAH market. The report
identifies the key trends shaping and driving the global PAH market. The report also
provides insight on the prevalent competitive landscape and the emerging players
expected to bring significant shift in the market positioning of the existing market
leaders. Most importantly, the report provides valuable insight on the pipeline products
within the global PAH sector. This report is built using data and information sourced
from proprietary databases, primary and secondary research and in house analysis by
GlobalData’s team of industry experts.

For further details, please click or add this link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-
Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782